Protagonist Therapeutics (PTGX) free cash flow

Free cash flow · fiscal 2025
$56.08M

Protagonist Therapeutics (PTGX) generated free cash flow of $56.08M in fiscal 2025 (the year ended December 31, 2025). That is 69.3% lower than the $182.80M of fiscal 2024. Figures as of 18 Nov 2026, 12:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$56.08M
Change on fiscal 2024
−69.3%
Highest on record
$182.80Mfiscal 2024
Lowest on record
-$108.97Mfiscal 2021
Fiscal years on record
122014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Protagonist Therapeutics free cash flow, in more detail

Across the 12 fiscal years on record (2014–2025), the highest was $182.80M in fiscal 2024 and the lowest -$108.97M in fiscal 2021.

History · 12 fiscal years

Free cash flow by fiscal year

Protagonist Therapeutics free cash flow, year by year

Protagonist Therapeutics (PTGX) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$56.08M 69.3% down
2024$182.80M—
2023-$70.85M—
2022-$108.93M—
2021-$108.97M—
2020-$72.96M—
2019-$42.49M—
2018-$50.43M 1,673.1% down
2017$3.21M—
2016-$30.32M—
2015-$14.78M—
2014-$8.04M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Protagonist Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Praxis Precision Medicines PRAX-$249.12M2025
Twist Bioscience TWST-$95.96M2026
Protagonist Therapeutics PTGX$56.08M2025
Krystal Biotech KRYS$188.91M2025
10x Genomics TXG$130.12M2025
HealthEquity HQY$408.32M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics free cash flow: questions and answers

What is Protagonist Therapeutics's free cash flow?

Protagonist Therapeutics (PTGX) generated free cash flow of $56.08M in fiscal 2025 (the year ended December 31, 2025). That is 69.3% lower than the $182.80M of fiscal 2024.

What are the highest and lowest free cash flow figures on record for Protagonist Therapeutics?

Across the 12 fiscal years on record (2014–2025), the highest was $182.80M in fiscal 2024 and the lowest -$108.97M in fiscal 2021.

How is Protagonist Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Protagonist Therapeutics it is on record here for 12 fiscal years, 2014 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.